15% of patients with MG are refractory to conventional treatment. Case reports and a few studies have demonstrated a potential benefit of rituximab in these cases. This study was done to assess the efficacy and the safety of rituximab in patients with MG in a real-life multicentric survey.
The researchers included in total Twenty-nine patients in the study. Out of the total sample size of 20 with anti‐AChR MG, five patients were with anti‐MuSK MG, and 4 with seronegative MG. MGFA‐PIS score was improved or better in 86.2% of patients after six months of treatment. The mean MMS increased from 68.8 to 83.1. A decrease in steroid dosage was effective in 57.9% of treated patients. In all, 42.8% of patients experienced adverse events: infections (21.4% of patients); infusion reaction (7%); bradycardia (3.7%); and cytopenia (7%).
The present study demonstrates the efficacy and safety of rituximab in patients with MG. Additional studies remain necessary to determine the role of rituximab in MG treatment’s pharmacopeia and establish precise recommendations for the infusion protocol.
Reference: https://onlinelibrary.wiley.com/doi/10.1111/ene.14391
